Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pharmaxis Ltd ( (AU:SNT) ) has issued an announcement.
Syntara Limited has received guidance from the FDA on the next stages of clinical development for its drug candidate amsulostat, which is being studied for the treatment of myelofibrosis. The FDA has recommended a Phase 2 trial with a control arm to gather additional safety and efficacy data, focusing on symptom improvements and spleen volume reductions. This guidance will help Syntara refine its clinical development plan and continue discussions with partners. The company is well-positioned with a strong pipeline and financial runway extending into 2027, and it plans to share ongoing clinical trial results in the coming months.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.12 price target. To see the full list of analyst forecasts on Pharmaxis Ltd stock, see the AU:SNT Stock Forecast page.
More about Pharmaxis Ltd
Syntara Limited is a clinical-stage drug development company that focuses on targeting extracellular matrix dysfunction using amine oxidase chemistry and other technologies. The company aims to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. Its lead candidate, amsulostat, is being developed for myelofibrosis, a bone marrow cancer, and has received Fast Track Designation from the FDA. Syntara is also advancing other drug candidates for various fibrotic and inflammatory diseases, and has previously developed two respiratory products that were sold in 2023.
Average Trading Volume: 9,779,384
Technical Sentiment Signal: Hold
Current Market Cap: A$92.78M
See more data about SNT stock on TipRanks’ Stock Analysis page.